Patient perceptions of their glycemic control and its influence on type 2 diabetes outcomes: an international survey of online communities
- PMID: 30863019
- PMCID: PMC6388747
- DOI: 10.2147/PPA.S186801
Patient perceptions of their glycemic control and its influence on type 2 diabetes outcomes: an international survey of online communities
Abstract
Purpose: This study aimed to assess awareness of glycated hemoglobin (A1C) testing and targets, perceived level of glycemic control and risk of complications, attitudes toward medications and self-management, and regimen-related distress in an international sample of patients with type 2 diabetes (T2D).
Methods: The descriptive study used a single time-point survey of adults in online health communities in the USA, Canada, the UK, Germany, Spain, and Mexico, who self-reported T2D diagnosed by a physician.
Results: In total, 661 patients participated. Awareness of their A1C value at last test varied considerably between countries (42%-89%), as did awareness of having an A1C target (26%- 70%). Self-reported A1C values were similar across US, Canadian, and European respondents (mean, 6.8%-7.3%). Approximately two-thirds of respondents from these countries (66%-71%) reported that their T2D was very or fairly well controlled, and few (5%-15%) expected to experience serious complications within 1 year. However, many respondents expected to experience microvascular (rather than macrovascular) complications in this time frame (eg, nerve pain, 5%-47%). Self-reported adherence to oral medication was generally high, with most respondents (86%-98%) taking their pills or tablets as directed by their healthcare provider, although for insulin injections adherence was lower in the USA (71%) and Mexico (78%) than in the other countries (86%-95%). The majority of respondents across countries (71%-79%) reported that taking injectable medications was not at all or a little burdensome. Respondents across countries appeared to be reasonably confident that they could adequately manage their blood sugar levels; despite this, a sizeable minority (21%-35%) had clinically significant levels of regimen-related distress.
Conclusion: Limited patient awareness of their A1C value and the potential complications of poorly controlled T2D, particularly regarding cardiovascular complications, may be a widespread problem. Furthermore, greater patient support may be needed to improve self-management of T2D and to reduce regimen-related distress.
Keywords: diabetes complications; diabetes mellitus; glycated hemoglobin; self-management; surveys; type 2.
Conflict of interest statement
Disclosure Kristina Simacek and Christopher Curran are employees of PatientsLikeMe, Inc. and hold stock options in Patients-LikeMe, Inc. They have received research funding (including conference support and consulting fees) from Abbvie, Accorda, Actelion, Alexion, Amgen, AstraZeneca, Avanir, Biogen, Boehringer Ingelheim, Celgene, EMD, Genentech, Genzyme, Janssen, Johnson & Johnson, Merck, Neuraltus, Novartis, Otsuka, Sanofi, Takeda, and UCB. They have received research grant funding from Kaiser Permanente, the Robert Wood Johnson Foundation, Sage Bionetworks, the AKU Society, and the University of Maryland. Peter Fenici and Ricardo Garcia-Sanchez are current and former employees of AstraZeneca, respectively and may own shares in AstraZeneca.
Figures
References
-
- World Health Organization . Global Report on Diabetes. Geneva: World Health Organization; 2016. [Accessed January 17, 2018]. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf.
-
- International Diabetes Federation Global guideline for type 2. Diabetes. 2012. [Accessed January 17, 2018]. Available from: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-....
-
- American Diabetes Association Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(Suppl 1):S1–S132. - PubMed
-
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21(4):438–447. - PubMed
-
- Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P, Clinical Guidelines Committee of the American College of Physicians Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218–231. - PubMed
LinkOut - more resources
Full Text Sources
